Betnovate
In brief
- In our pharmacy you can buy Betnovate without a prescription, with delivery throughout the United Kingdom and discreet packaging available. Betnovate is a prescription-only medicine (POM) in the UK.
- Betnovate (betamethasone valerate) is used for inflammatory skin conditions such as eczema, psoriasis, lichen planus and dermatitis; it is a potent topical corticosteroid that works by activating glucocorticoid receptors to reduce inflammation, itching and redness (anti‑inflammatory, immunosuppressive and vasoconstrictive effects).
- Usual dosage: apply a thin film to the affected area once or twice daily (typically 1–2 times daily) for up to 2–4 weeks; use the smallest amount for the shortest duration necessary and avoid prolonged or occluded use.
- Form of administration: topical — cream, ointment or lotion/scalp applicator (commonly 0.1% strength; available in tubes and bottles; also in combination formulations with antimicrobials).
- Onset time: symptom relief (reduced itching and redness) is often noticed within hours to 48 hours, with more marked improvement over several days.
- Duration of action: the topical effect generally lasts about 24 hours, which is why once or twice daily dosing is used; typical treatment courses are 1–2 weeks and rarely exceed 4 weeks.
- Alcohol warning: there is no specific interaction with alcohol for topical use, but avoid excessive alcohol if large‑area or prolonged treatment is being used (increased risk of systemic absorption and complications) and follow medical advice.
- The most common side effect is transient burning or stinging at the application site; other common effects include itching, irritation, dryness and, with prolonged or widespread use, skin thinning and stretch marks.
- Would you like to try Betnovate without a prescription?
Basic Betnovate information
- INN (international nonproprietary name): Betamethasone valerate
- Brand names available in the United Kingdom: Betnovate (cream, ointment, scalp application); Betnovate-N (with neomycin)
- ATC code: D07AC01
- Forms and dosages: Cream 0.1% (tube 15g, 30g, 100g); ointment 0.1% (tube 15g, 30g, 100g); lotion/scalp applicator 0.1% (bottle 30ml, 60ml); Betnovate-N (with neomycin) is a combination product
- Manufacturers in the United Kingdom: GlaxoSmithKline (GSK)
- Registration status in the United Kingdom: Prescription-only medicine (POM)
- OTC / Rx classification: Prescription-only medicine (POM)
What Betnovate is: active ingredient, strength and classification
Core product identity
Betnovate contains the INN betamethasone valerate, a topical corticosteroid used for inflammatory skin conditions.
The product is classified under ATC code D07AC01, meaning it is a strong topical corticosteroid (group III).
Typical marketed strength is 0.1% w/w in cream and ointment formulations, with scalp lotions at the same strength.
Because of this potency, Betnovate is a prescription-only medicine in the UK.
It is not suitable for casual or cosmetic uses and should not be used for skin whitening.
The strong steroid classification guides prescribers to reserve Betnovate for moderate to severe flares when milder agents have failed.
Betnovate should be treated as a targeted short-term therapy rather than a general skin moisturiser or maintenance product.
Formulations and pack sizes
Available formats
Betnovate is available in several formats: cream, ointment, scalp lotion and combination tubes with antimicrobials.
Typical UK pack sizes are 15g, 30g and 100g tubes for cream and ointment, and 30–60ml bottles for scalp lotion.
Betnovate‑N is a combination product that adds neomycin.
The table below summarises form, strength and common pack sizes.
| Form | Strength | Common pack sizes |
|---|---|---|
| Cream | 0.1% w/w | 15g, 30g, 100g tube |
| Ointment | 0.1% w/w | 15g, 30g, 100g tube |
| Lotion / scalp applicator | 0.1% w/w | 30ml, 60ml bottle |
| Combination tubes (e.g. Betnovate‑N) | 0.1% plus antimicrobial | Varies by product |
Indications — conditions where Betnovate is commonly prescribed
Indications
Betnovate is indicated for a range of inflammatory dermatoses when a strong topical steroid is appropriate.
- Eczema flares (atopic and contact dermatitis) requiring a strong preparation for short‑term control.
- Psoriasis plaques where moderate to strong corticosteroid therapy is indicated.
- Lichen planus and other inflammatory dermatoses with noticeable redness and itching.
- Severe seborrhoeic dermatitis of the scalp treated with the lotion formulation.
- The combination product Betnovate‑N is intended where secondary infection is suspected; check extra contraindications before use.
Betnovate is for short‑term use to control active inflammation, not for maintenance or cosmetic whitening.
When to see the GP: if the rash does not improve after two weeks of correctly applied treatment, if signs of infection develop, or if the condition recurs frequently.
Dosage regimens and practical application guidance
Typical regimens and real‑world tips
For most conditions apply a thin film of cream or ointment once or twice daily to affected areas for 1–2 weeks, rarely exceeding 4 weeks.
Scalp lotion is applied sparingly once or twice daily as directed by the prescriber.
Use the smallest effective amount and avoid occlusion unless advised by a clinician for severely inflamed areas.
Children should receive the minimal quantity for the shortest duration and Betnovate is usually not recommended for children under one year.
When stopping after prolonged use, taper frequency gradually rather than abrupt cessation to reduce rebound inflammation risk.
The fingertip unit (FTU) method helps quantify dose: one FTU (from fingertip to first crease) treats about two adult hand‑sizes.
Missed dose: apply as soon as you remember but do not double the next application to catch up.
Overuse increases the risk of systemic effects such as HPA axis suppression, especially with large‑area or prolonged treatment.
Contraindications, cautions and special populations
Who should avoid Betnovate or use with caution
Absolute contraindications include hypersensitivity to betamethasone valerate or any excipient and untreated viral, fungal or bacterial skin infections.
Do not use on rosacea, acne vulgaris, perioral dermatitis, tuberculous skin lesions, or in the eyes.
Relative contraindications requiring careful monitoring include extensive area use, prolonged therapy, impaired skin barrier and elderly patients at higher atrophy risk.
Infants are more vulnerable and Betnovate is usually not recommended under 1 year of age without specialist advice.
Use in pregnancy and lactation only under medical supervision, weighing maternal benefit against potential risk.
Betnovate‑N carries additional risks such as neomycin ototoxicity.
Side effects, monitoring and when to seek help
Practical adverse effect guidance for patients
Common and usually mild reactions include transient burning, stinging, itching, dryness and peeling at the application site.
Prolonged or extensive use can cause skin atrophy, striae, folliculitis, telangiectasia and pigmentation changes.
Delayed wound healing and secondary infection are possible if steroid use masks symptoms of an underlying infection.
Systemic effects such as HPA axis suppression or Cushingoid features are rare but can occur with excessive use over large areas or in young children.
Advice to patients: stop treatment and seek medical review if the rash worsens, spreads, or signs of infection appear (pus, increasing pain, fever).
Red flags: new systemic symptoms such as unexplained weight gain, mood changes, fatigue or muscle weakness warrant urgent medical assessment.
Monitoring timeline: reassess after two weeks of therapy; record improvement, side effects and plan to step down or stop if controlled.
Interactions and combination products (Betnovate‑N)
Practical points for combination formulations
Betnovate‑N combines betamethasone valerate with neomycin and is used when bacterial infection is suspected alongside inflammation.
Betnovate‑N carries extra contraindications: neomycin has a risk of ototoxicity.
Topical products rarely interact systemically, but concurrent systemic corticosteroids increase cumulative steroid exposure and systemic risk.
Known hypersensitivity to neomycin should be checked before use.
| Product | Extra cautions | Typical indication |
|---|---|---|
| Betnovate | Standard topical steroid precautions | Inflammatory dermatoses without suspected infection |
| Betnovate‑N (with neomycin) | Neomycin allergy; ototoxicity risk if used near ear canals | Suspected secondary bacterial infection |
Comparison with alternatives
Choosing potency and therapeutic alternative
Topical steroid choice depends on lesion severity, anatomical site and patient age.
Betnovate occupies the strong (group III) niche and is appropriate for moderate to severe flares when milder steroids fail.
More potent competitors include clobetasol propionate (super‑potent) which is reserved for severe, resistant disease.
Mometasone furoate offers a moderate‑strong option, while hydrocortisone preparations are used for mild disease and sensitive sites.
Practical tip: stepping down to a milder steroid for maintenance once inflammation is controlled reduces atrophy risk.
| Agent | Relative potency | When to use |
|---|---|---|
| Clobetasol (Dermovate) | Super‑potent | Severe, resistant plaques |
| Betamethasone valerate (Betnovate) | Strong (Group III) | Moderate‑severe flares |
| Mometasone (Elocon) | Moderate‑Strong | Moderate inflammation |
| Hydrocortisone 1%/2.5% | Mild | Mild eczema, sensitive areas |
Storage and disposal
Safe handling instructions
Store Betnovate at 15–25°C, protect from light and keep the container tightly closed.
Do not freeze and keep all topical steroids out of reach of children.
Unused or expired topical steroids should be returned to a pharmacy for safe disposal rather than being thrown in household waste.
Proper disposal reduces environmental steroid contamination and prevents accidental use by others.
Legal status and availability in the UK
Betnovate is a prescription-only medicine (POM) in the UK and is regulated by the MHRA.
In our online pharmacy, Betnovate is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Counselling points and follow-up
Betnovate is a strong topical steroid and should be used for short periods only.
Apply it using the fingertip unit and avoid use on the face, groin or underarms unless directed by a clinician.
Stop and seek review if the rash spreads or signs of infection occur.
Book a GP review if there is no improvement after two weeks or if repeat prescriptions are needed.
Quick reference FAQ and clinical summary
Quick answers
Is it prescription‑only? Yes — Betnovate is prescription‑only in the UK and regulated by the MHRA.
How long to use it? Typically 1–2 weeks; treatment rarely exceeds 4 weeks and tapering is advised after prolonged use.
Can children use it? Use with caution; generally not recommended under 1 year and apply the smallest effective amount in older children.
What if the rash worsens? Stop application and seek medical review for possible secondary infection or alternative diagnosis.
Storage? Store at 15–25°C, protect from light and keep out of reach of children.
One‑line clinical summary: Betamethasone valerate 0.1% (Betnovate) is a strong topical corticosteroid for short‑term control of inflammatory dermatoses; monitor for local and systemic effects when used over large areas or in children.
Delivery across the United Kingdom
| City | Region | Delivery time |
|---|---|---|
| London | Greater London | 9–21 days |
| Birmingham | West Midlands | 9–21 days |
| Manchester | Greater Manchester | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | West Yorkshire | 9–21 days |
| Liverpool | Merseyside | 9–21 days |
| Sheffield | South Yorkshire | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Bristol | South West England | 9–21 days |
| Newcastle Upon Tyne | North East England | 9–21 days |
| Nottingham | Nottinghamshire | 9–21 days |
| Southampton | South East England | 9–21 days |
| Brighton | East Sussex | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Cardiff | Wales | 9–21 days |
